Orient EuroPharma Statistics

Total Valuation

Orient EuroPharma has a market cap or net worth of TWD 4.24 billion. The enterprise value is 8.31 billion.

Market Cap	4.24B
Enterprise Value	8.31B

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	Jul 19, 2024

Share Statistics

Orient EuroPharma has 86.75 million shares outstanding. The number of shares has increased by 0.23% in one year.

Shares Outstanding	86.75M
Shares Change (YoY)	+0.23%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.27%
Float	55.70M

Valuation Ratios

The trailing PE ratio is 29.30.

PE Ratio	29.30
Forward PE	n/a
PS Ratio	0.94
PB Ratio	0.80
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.01, with an EV/FCF ratio of -39.41.

EV / Earnings	57.39
EV / Sales	1.85
EV / EBITDA	24.01
EV / EBIT	63.23
EV / FCF	-39.41

Financial Position

The company has a current ratio of 1.00, with a Debt / Equity ratio of 0.84.

Current Ratio	1.00
Quick Ratio	0.60
Debt / Equity	0.84
Debt / EBITDA	13.47
Debt / FCF	-23.67
Interest Coverage	1.48

Financial Efficiency

Return on equity (ROE) is 4.22% and return on invested capital (ROIC) is 0.98%.

Return on Equity (ROE)	4.22%
Return on Assets (ROA)	0.83%
Return on Capital (ROIC)	0.98%
Revenue Per Employee	13.27M
Profits Per Employee	427,029
Employee Count	339
Asset Turnover	0.38
Inventory Turnover	1.89

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +14.79% in the last 52 weeks. The beta is 0.41, so Orient EuroPharma's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	+14.79%
50-Day Moving Average	48.40
200-Day Moving Average	43.74
Relative Strength Index (RSI)	46.40
Average Volume (20 Days)	90,797

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Orient EuroPharma had revenue of TWD 4.50 billion and earned 144.76 million in profits. Earnings per share was 1.67.

Revenue	4.50B
Gross Profit	2.21B
Operating Income	155.88M
Pretax Income	341.05M
Net Income	144.76M
EBITDA	321.43M
EBIT	155.88M
Earnings Per Share (EPS)	1.67

Full Income Statement

Balance Sheet

The company has 1.58 billion in cash and 4.99 billion in debt, giving a net cash position of -3.42 billion or -39.37 per share.

Cash & Cash Equivalents	1.58B
Total Debt	4.99B
Net Cash	-3.42B
Net Cash Per Share	-39.37
Equity (Book Value)	5.95B
Book Value Per Share	61.05
Working Capital	4.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -143.75 million and capital expenditures -67.07 million, giving a free cash flow of -210.82 million.

Operating Cash Flow	-143.75M
Capital Expenditures	-67.07M
Free Cash Flow	-210.82M
FCF Per Share	-2.43

Full Cash Flow Statement

Margins

Gross margin is 49.15%, with operating and profit margins of 3.47% and 3.22%.

Gross Margin	49.15%
Operating Margin	3.47%
Pretax Margin	7.58%
Profit Margin	3.22%
EBITDA Margin	7.15%
EBIT Margin	3.47%
FCF Margin	-4.69%

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 2.04%.

Dividend Per Share	1.00
Dividend Yield	2.04%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.23%
Shareholder Yield	1.82%
Earnings Yield	3.41%
FCF Yield	-4.97%

Dividend Details

Stock Splits

The last stock split was on July 28, 2010. It was a forward split with a ratio of 1.16.

Last Split Date	Jul 28, 2010
Split Type	Forward
Split Ratio	1.16

Scores

Orient EuroPharma has an Altman Z-Score of 0.88. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.88
Piotroski F-Score	n/a